Author

A. Grayson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell signaling & trafficking· 2 Approach:experimental assay· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Assay:flow cytometry· 1

Frequent Co-Authors

A. N. Alilin· 1 shared A. T. Satpathy· 1 shared B. Capaldo· 1 shared B. Gryder· 1 shared C. A. Lareau· 1 shared D. J. VanderWeele· 1 shared D. R. Littman· 1 shared H. Paidassi· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. N. Alilin

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Microbiota-instructed regulatory T cell differentiation is mediated by a distinct RORγt+ antigen presenting cell subset

R. Kedmi, T. Najar, K. R. Mesa, A. Grayson, L. Kroehling, Y. Hao, S. Hao, M. Pokrovskii, M. Xu, J. Talbot, J. Wang, J. Germino, C. A. Lareau, A. T. Satpathy, M. S. Anderson, , D. R. Littman

This study identifies a distinct RORγt+ antigen presenting cell subset that mediates microbiota-driven regulatory T cell differentiation, revealing a mechanism for maintaining immune tolerance.

bioRxiv · Nov 19, 2021 · PreprintImmunology

Targeting the PI3K/AKT pathway overcomes enzalutamide resistance by inhibiting induction of the glucocorticoid receptor

R. M. Adelaiye-Ogala, B. Gryder, Y. T. M. Nguyen, A. N. Alilin, A. Grayson, K. H. Jansson, M. L. Beshiri, S. Agarwal, B. Capaldo, J. A. Rodriguez-Nieves, K. Kelly, D. J. VanderWeele

This study shows that inhibiting the PI3K/AKT pathway blocks GR induction and overcomes enzalutamide resistance in prostate cancer by remodeling chromatin and enhancing AR activity.

bioRxiv · Oct 1, 2019Cancer Biology